#South Korea #Seoul #Energenesis #ENERGI-F703DFU #Yoo Young Pharm

Major Collaboration on ENERGI-F703DFU in South Korea

Energenesis Biomedical Co., Ltd. has taken a significant step toward expanding its market presence by signing a Memorandum of Understanding (MOU) with Yoo Young Pharm Co., Ltd., based in South Korea. This agreement is set to explore a collaborative approach for the development, registration, and commercialization of the innovative therapeutic candidate, ENERGI-F703DFU.

The Details Behind the MOU

The MOU establishes a framework that will facilitate ongoing discussions aimed at forming a definitive agreement. According to the terms discussed, Yoo Young Pharm is expected to obtain rights for the development and commercialization of ENERGI-F703DFU within South Korea. This partnership aims to harness Energenesis's comprehensive data package, which includes critical Phase III clinical trial data, along with Yoo Young Pharm's expansive clinical and commercial networks in the region.

This strategic alliance is not merely a partnership but rather an effort to accelerate the development of ENERGI-F703DFU, a topical small-molecule gel scientifically designed to promote healing in diabetic foot ulcers. By modulating cellular energy pathways, this therapeutic candidate seeks to enhance the healing processes in affected individuals.

Understanding ENERGI-F703DFU

Energenesis’s ENERGI-F703DFU is intended to specifically address diabetic foot ulcers by increasing intracellular ATP levels at the wound site. The objective is to support not only epithelial cell migration but also activate the intrinsic repair mechanisms that are crucial for wound healing.

In a notable post-hoc analysis of the Phase II study numbered NCT02672436, the results indicated that patients who met the inclusion criteria for Phase III exhibited a remarkable complete wound closure rate of 36.7% when treated with ENERGI-F703DFU compared to just 9.1% for the vehicle control group over a treatment span of 12 weeks (with P<0.05), underscoring the candidate's therapeutic potential.

Profiles of the Organizations

Energenesis Biomedical

Energenesis Biomedical Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the innovative development of therapeutics aimed at restoring cellular energy and triggering natural repair processes. With unique small-molecule innovations and AI-driven approaches to drug repurposing, Energenesis addresses significant unmet medical needs across various therapeutic domains, including chronic wounds and neurodegenerative diseases.

Yoo Young Pharm

Yoo Young Pharm Co., Ltd., founded in 1981, represents a fully integrated South Korean pharmaceutical enterprise, possessing robust capabilities that encompass in-house research and development, compliant global manufacturing, and commercialization strategies. Renowned for their leadership roles in musculoskeletal care, metabolic diseases, and tissue regeneration, Yoo Young Pharm is committed to advancing innovative therapeutic solutions and delivering high-quality healthcare across various markets.

Looking Ahead

While the MOU lays the groundwork for the ongoing discussions, it also emphasizes that any ultimate agreement will be subject to negotiation between Energenesis Biomedical and Yoo Young Pharm. Both companies are focused on creating a successful collaboration that enhances drug availability and therapeutic innovation in South Korea's competitive pharmaceutical landscape.

As the progress unfolds, further updates from both firms are anticipated, signaling advancements that could transform treatment options for diabetic foot ulcer patients. In the realm of biopharmaceuticals, such collaborations often pave the way for breakthroughs that address long-standing healthcare challenges.

In conclusion, the partnership represents a promising opportunity for both Energenesis and Yoo Young Pharm as they work towards a common goal of enhancing patient outcomes through innovative solutions like ENERGI-F703DFU.